Yahoo · Nov 10, 2026
Precigen Posts Strong Q3: PAPZIMEOS Net Revenue Rose 37%; Positive Cash Flow Achieved Ahead of Schedule
* Widespread adoption underway * Five-year data suggest lasting disease control and prolonged freedom from surgery * New competing product said to face substantial uncertaintyBiotech in the News: The LongviewGERMANTOWN, MD / ACCESS Newswire / November 10, 2026 / Precigen Inc. (Nasdaq:PGEN) reported sharply improved third-quarter results late last week, driven by continuing rapid uptake of its flagship therapy PAPZIMEOS®, as the company achieved positive cash flow a quarter ahead of schedule and

